Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GLP North
Toronto, Ontario, Canadaglpnorth.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
GLP North is a Canadian supplier and distributor of independently tested, ready-to-use peptide research products. The company specializes in GLP-1 and multi-receptor agonist peptide pen formats, with its primary product offerings being Semaject (a research-grade semaglutide pen) and Retaject (a research-grade retatrutide pen). GLP North focuses on providing Canadian researchers with domestic fulfillment, third-party analytical testing, and publicly accessible batch documentation to streamline metabolic health research. Its products are marketed strictly for research and development purposes.
- Therapeutic areas
- Metabolic DisordersEndocrinology
- Modalities
- PeptidesBiologic
- Industry
- Chemicals & Materials
Beyond the preview
Go deeper on GLP North.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLP North.